Scientists from the Dana-Farber Cancer Institute have found that one-third of penile cancer patients with limited lymph node metastases respond to immunotherapy. Research published Journal of the National Cancer Institute.
Penile cancer is a rare disease that accounts for less than 1% of all diagnosed malignant tumors. Treatment options are limited, usually starting with platinum-based chemotherapy, which has many side effects.
In a new study, scientists evaluated the effectiveness of immunotherapy drugs known as immune checkpoint (ICT) inhibitors. They analyzed data from 92 patients who took these drugs in various trials in several countries.
The most common ICTs are pembrolizumab, nivolumab, and cemiplimab, with some patients receiving combined therapy with nivolumab and ipilimumab. The authors found that 13% of all patients and 35% of patients with limited lymph node metastases responded to treatment.
Full-fledged clinical trials evaluating the efficacy of ICT in penile cancer are difficult due to the rarity of this type of tumor. More research is needed to understand why drugs work in some patients and not in others.
ancient scientists developed The most dangerous cancer treatment in women.